Tevard Biosciences

Tevard Biosciences

A Cambridge Massachusetts based biotechnology company founded in 2017 developing gene therapy platforms to target rare and unmet diseases.

Tevard Biosciences was founded by Daniel Fischer and Warren Lammert, parents of girls with Dravet Syndrome and Harvey Lodish, a professor at MIT and Whitehead Institute for Biomedical Research.

Tevard Biosciences is developing gene therapy platforms to target rare diseases such as Dravet syndrome and disorders caused by haploinsufficiency and/or premature stop codons, which traditional gene therapy approaches do not target. Dravet syndrome is also known as Severe Myoclonic Epilepsy of Infancy (SMEI), a condition caused by a mutation in the SCN1A gene required for brain cell function, in 85% of cases.

The company is housed at LabCentral, a shared laboratory space for launching life-sciences and biotech startups. Tevard Biosciences won a Pfizer-sponsored LabCentral “Golden Ticket” in 2018, which provides one year of bench space for one scientist with infrastructure and services.

Timeline

2007

Tevard Biosciences was founded.

People

Name
Role
LinkedIn

David Fischer

Founder

Harvey Lodish

Founder

Jeff Walsh

Member Board Of Directors

Warren Lammert

Founder

Further reading

Title
Author
Link
Type
Date

Daniel Fischer - Tevard Biosciences | Biotech Showcase Speaker

EBD Group

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.